[Staphylococcal pneumonia].
In January to December 2000, a total of 15 (8.8%) patients with staphylococcal community-acquired pneumonia (CAP), 13 (27.7%) patients with staphyloccocal nosocomial pneumonia (NP) that occurred at general units (GU), and 9 (50%) patients with GU that occurred under artificial ventilation (AV) at intensive care units (ICU) were followed up. Meticillin-resistant S. aureus strains were isolated in 6.7, 38.5, and 55.6% of cases, respectively. As compared with pneumococcal CAP, staphyloccocal CAP were more frequently characterized by the severe course of the disease (46.7% versus 15.4%), bilateral lesion (33.3% versus 5.1%), and the presence of complications (66.7% versus 30.8%). Staphyloccocal NP that had occurred at GU, as compared to that at ICU also showed the severe course of the disease (46.2% versus 2.9%), bilateral lesion (30.7% versus 0%), and developed complications (75% versus 25%). Staphylococcal NP developed under AV at ICU had no specific features as compared with NP of another etiology. Oxacillin and first-second-generation cephalosporins remain to be the drugs of choice when meticillin-sensitive S. aureus strains are isolated; lincomycin and erythromycin being alternative agents against these strains. Glycopeptides are the drugs of choice when meticillin-resistant S. aureus strains are isolated, its alernatives are linesolide or rifampicin. High mortality rates due to staphylococcal pneumonia are preserved. These are 7.1% in CAP, 7.7 and 66.7 in staphylococcal NP occurring at GU and under AV at ICU, respectively.
L I
LI
Dvoretskiĭ
S V
SV
Iakovlev
V V
VV
Kaminskiĭ
M P
MP
Suvorova
D058186:Acute Kidney Injury / Q000453:epidemiology; D000747:Anemia, Hypochromic / Q000453:epidemiology; D000890:Anti-Infective Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000453:epidemiology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007022:Hypotension / Q000453:epidemiology; D008168:Lung / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*; D012131:Respiratory Insufficiency / Q000453:epidemiology / Q000503:physiopathology; D015996:Survival Rate
D000890:Anti-Infective Agents